ArticleCase reports in psychiatry2026
Possible Improvement of Tardive Dyskinesia and Negative Symptoms With Lurasidone Augmentation in a Treatment-Resistant Schizophrenia Patient.
Article in Case reports in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Possible Improvement of Tardive Dyskinesia and Negative Symptoms With Lurasidone Augmentation in a Treatment-Resistant Schizophrenia Patient.Case reports in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tardive dyskinesia (TD) is a cluster of symptoms affecting orofacial, truncal, and extremity regions following prolonged exposure to antidopaminergic agents and may be life-threatening in severe cases. It is most commonly observed in patients receiving long-term antipsychotic treatment, such as individuals with schizophrenia. Lurasidone is a relatively novel antipsychotic that has been reported to induce tardive syndromes in patients with schizophrenia and bipolar disorder and has also been used as an augmentation strategy in treatment-resistant schizophrenia. In this report, we present an intriguing case in which TD improved following the addition of lurasidone to the patient's existing treatment, accompanied by a reduction in negative psychotic symptoms. The patient's Abnormal Involuntary Movement Scale (AIMS) score decreased from 20 to 8-9 after the initiation and subsequent dose increase of lurasidone. Additionally, the Positive and Negative Syndrome Scale (PANSS) total score decreased from 171 to 148, with particularly notable improvement in the negative symptom subscale. The beneficial effect of lurasidone on TD is hypothesized to be related to various receptor interactions of the current treatment, as well as 5-HT
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.